SCHEMBL5872307

SCHEMBL5872307

CCn1c(=O)c([I+]c2ccccc2)c([O-])c2cccnc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
PDE4D Q08499 6/20 0.39
PDE4A P27815 5/20 0.39
PDE4B Q07343 5/20 0.39
PDE4C Q08493 5/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 3/20 0.36
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
PKM P14618 1/20 0.36
TSHR P16473 1/20 0.36
MAPK8 P45983 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5872030 0.91 PDE4D (0.43) PDE4DPDE4APDE4BPDE4CMEN1
SCHEMBL5871960 0.87 CNR1 (0.45) PDE4DPDE4APDE4BPDE4CMEN1
SCHEMBL7945856 0.85 HDAC1 (0.48) PDE4DPDE4APDE4BPDE4CMEN1
SCHEMBL5871920 0.84 FEN1 (0.45) PDE4DPDE4APDE4BPDE4CKDM4E
SCHEMBL5872204 0.82 MAPT (0.53) MEN1KMT2AKDM4EMAPTTP53
SCHEMBL5871709 0.80 FEN1 (0.50) PDE4DPDE4APDE4BPDE4CKDM4E
SCHEMBL7945833 0.79 L3MBTL1 (0.51) MAPTTP53ALDH1A1LMNATSHR
SCHEMBL5871439 0.79 LIPG (0.43) MEN1KMT2AMAPTALDH1A1LMNA
SCHEMBL7954338 0.78 PTGDR2 (0.41) CCNA2CDK2PDE4DPDE4APDE4B
SCHEMBL5872001 0.75 GAA (0.42) CCNA2CDK2PDE4DPDE4BMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071187-B2 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2006-07-04 US disclosed
US-20040214853-A1 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-10-28 US disclosed
EP-1426374-A1 NAPHTHYRIDINE DERIVATIVE OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214853-A1 Naphthyridine derivatives MT-ND1, OPRD1, NR0B1 CCNA2 1725/4885CDK2 1928/4885PDE4D 1360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.